Picton Mahoney Asset Management Sells 32,587 Shares of Masimo Corporation $MASI

Key Points

• Picton Mahoney sold 32,587 shares of Masimo in Q3, trimming its stake by 73.1% and leaving 11,970 shares valued at about $1.77 million.
• Other institutional activity was significant: Westfield Capital boosted its position to 1,181,203 shares (~$198.7M) and Jupiter opened a ~$12.49M stake, with institutional investors owning 85.96% of MASI.
• Stock and analyst picture: Masimo has a $9.42B market cap, a 52‑week range of $125.94–$183.49 and a negative P/E (‑16.65); analysts hold a consensus "Hold" with an average target around $181 amid recent downgrades.

Picton Mahoney Asset Management trimmed its holdings in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 73.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,970 shares of the medical equipment provider's stock after selling 32,587 shares during the period. Picton Mahoney Asset Management's holdings in Masimo were worth $1,766,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of MASI. Jupiter Asset Management Ltd. acquired a new stake in Masimo in the third quarter worth $12,491,000. Westfield Capital Management Co. LP boosted its position in shares of Masimo by 75.9% during the 2nd quarter. Westfield Capital Management Co. LP now owns 1,181,203 shares of the medical equipment provider's stock worth $198,702,000 after purchasing an additional 509,724 shares in the last quarter. 4D Advisors LLC boosted its position in shares of Masimo by 50.0% during the 2nd quarter. 4D Advisors LLC now owns 45,000 shares of the medical equipment provider's stock worth $7,570,000 after purchasing an additional 15,000 shares in the last quarter. ING Groep NV acquired a new stake in shares of Masimo in the 3rd quarter valued at about $3,069,000. Finally, Citigroup Inc. increased its position in Masimo by 133.5% in the 3rd quarter. Citigroup Inc. now owns 116,672 shares of the medical equipment provider's stock valued at $17,215,000 after buying an additional 66,710 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Up 0.1%

MASI opened at $175.46 on Friday. Masimo Corporation has a fifty-two week low of $125.94 and a fifty-two week high of $183.49. The firm has a market capitalization of $9.42 billion, a P/E ratio of -16.65, a PEG ratio of 1.78 and a beta of 1.21. The company's 50-day moving average is $146.38 and its 200 day moving average is $144.69. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.49 and a quick ratio of 1.92.

Wall Street Analyst Weigh In

Several research analysts have issued reports on MASI shares. Wells Fargo & Company lowered Masimo from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $190.00 to $180.00 in a report on Wednesday, February 18th. Stifel Nicolaus set a $180.00 target price on Masimo in a report on Tuesday, February 17th. Bank of America assumed coverage on shares of Masimo in a research note on Monday, November 17th. They set a "neutral" rating and a $162.00 price target for the company. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Monday, December 1st. Finally, Piper Sandler cut shares of Masimo from an "overweight" rating to a "hold" rating and set a $180.00 price objective for the company. in a report on Tuesday, February 17th. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $181.17.

About Masimo

Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.